Reports Q2 revenue $20.2M, consensus $5.15M.”Following successful completion of the planned Phase 1 enrollment in the HPN217 trial, we are eager to reach additional important milestones in 2023,” said Julie Eastland, President and CEO of Harpoon Therapeutics. “We are on track to present data from our two TriTAC clinical programs later this year at leading medical conferences and select the Phase 2 monotherapy regimens for both HPN217 and HPN328. Harpoon’s financial resources are expected to fund current operations into the second half of 2024 and we remain focused on advancing our key programs.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HARP:
- Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
- Harpoon Therapeutics appoints Haibo Wang as SVP, business
- Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
- Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma